الفهرس 
Introduction and Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
Aim of the work
To study the effect of carvedilol on systolic left ventricular performance and cardiac electrical abnormalities in idiopathic dilated and ischemic cardiomyopathy.
Conclusion
The addition of carvedilol to other anti failure therapy for 6-12 months in patients with chronic heart failure with New York Heart Association (NYHA) class (II-IV) due to either dilated or ischemic cardiomyopathy reduces heart rate, systolic blood pressure, left ventricular sizes, increases left ventricular ejection fraction, protects against progressive left ventricular dilatation, improves clinical status and functional class.
Furthermore it has been showed that effect of carvedilol with previously mentioned parameters in additive and equal in magnitude to those achieved by classic anti failure measures.
These beneficial effects on left ventricular systolic function provide further evidence of the benefit of beta-blockade “carvedilol” in addition to standard treatment for heart failure, including ACE inhibitors.